TLE3 and acute myeloid leukemia: Further, our studies of TLE3 KD in primary patient AML cells suggest that compounds that target the interaction of the C-terminal VWRPY domain of RUNX1 with the WD40 β-propeller domain of TLE3, or the domains by which TLE3 undergoes oligomerization, may also be beneficial.